Aug. 22 /PRNewswire/ -- Maxygen (Nasdaq: MAXY - news) today announced that it has been issued U.S. Patent No. 6,096,548 describing use of its proprietary MolecularBreeding(TM) directed molecular evolution technologies for developing viral vectors with enhanced ability for uptake into specific target cells. The patented methods may be useful for developing improved vaccine and gene therapy vectors.
Maxygen recently validated its capabilities in vector evolution in a paper that was published in the August issue of Nature Genetics. In this study, Maxygen scientists successfully evolved a commonly-used retroviral vector for novel uptake into a target cell. This example revealed that Maxygen's MolecularBreeding(TM) directed molecular evolution technologies could be used to optimize vectors for gene therapy and vaccine applications.
Maxygen, Inc., headquartered in Redwood City, CA, is a public biotechnology company focused on creating novel products using its proprietary MolecularBreeding(TM) directed molecular evolution technologies for a broad range of industries. Maxygen's proprietary technologies bring together the advances in molecular biology and classical breeding while capitalizing on the large amount of genetic information generated by genomics. Maxygen's target markets include protein pharmaceuticals, preventative and therapeutic vaccines, chemicals and agriculture. Maxygen has strategic collaborations with several companies including Novo Nordisk, DuPont/Pioneer Hi-Bred, DSM, AstraZeneca, and Rio Tinto as well as governmental funding from DARPA and NIST-ATP. |
